Board Advisors
Don Rindell
Mr. Rindell has held numerous senior executive roles in the management of life science companies, including VP of Corporate Development & Strategic Planning for Advanced Tissue Sciences, VP of for Global Business Management for Braun/Thermoscan, a division of the Gillette Company, Executive Director of Business Development at Amylin Pharmaceuticals. Mr. Rindell is currently leading Global Device Business Development for Bristol Myers Squibb and is also the Managing Director of Camino International, LLC, a life science consultancy.
Gail Naughton
Dr. Naughton founded Histogen, Inc. in 2007, and currently serves as Chief Scientific Officer and Chief Business Development Officer for the Company. She has spent more than 30 years extensively researching the tissue engineering process, holds more than 100 U.S. and foreign patents and has been extensively published in the field.
​
She previously served as co-founder and co-inventor of Advanced Tissue Sciences, a manufacturer of human skin for wound healing and skin treatments. At ATS Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. While serving as an officer and director of the Company, Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch
Eddie Rodriguez
Eddie Rodriguez is a partner at Teal Ventures, an early stage venture capital fund focused on disruptive innovation in digital/ mobile health and medical devices. Prior to joining Teal Ventures, Eddie was a partner at several national law firms and a recognized corporate attorney in the venture capital and M&A fields. Eddie has represented countless startup and emerging growth companies throughout their life cycles and numerous private and public companies in M&A transactions, in industries including healthcare, medical devices, technology, fin-tech, e-commerce and telecommunications. Eddie has also co-founded several companies in the medical device and technology areas. He has also been an active investor in early stage companies in various industries.
​
Eddie received his JD from Stanford Law School, where he was the Editor-In-Chief of the Stanford Journal of International Law and the Articles Editor of the Stanford Law and Policy Review. He holds a B.A. from the University of California, Los Angeles.